Omalizumab 'relieves' aspirin-exacerbated respiratory disease

Small crossover study results suggest drug might be an important therapeutic candidate, researchers say

Omalizumab reduces aspirin hypersensitivity and lowers leukotriene E4 levels in patients with aspirin-exacerbated respiratory disease (AERD), according to results of a small study.

aspirin tablets

Japanese researchers evaluated the efficacy of omalizumab against the overproduction of leukotriene E4 (LTE4) following aspirin challenge, severe upper and lower respiratory symptoms, and aspirin hypersensitivity in a crossover trial of 16 patients (median age, 53 years) with AERD.

Compared with the placebo phase, there was a significant reduction in the overall production of LTE4